Swedish company IRLAB Therapeutics has been awarded funding of over $2 million from The Michael J Fox Foundation for Parkinson’s Research (MJFF).
The grant will be used to conduct a Phase I clinical study of IRL757, a drug candidate in development as a novel treatment of apathy.
The grant was awarded under MJFF’s program ‘Parkinson’s Disease Therapeutics Pipeline Program.’ This programme seeks to advance promising therapeutic developments that address unmet medical needs in people with Parkinson’s disease.
“The MJFF is always looking for ways to address the unmet needs of people with Parkinson’s. IRLAB’s novel approach to treating apathy has the potential to alter an impactful symptom for people affected by Parkinson’s – both patients and families – offering relief where it is currently difficult to find. We look forward to seeing this research progress,” said MJFF’s Senior Vice President of Clinical Research Catherine Kopil.
IRL757 has completed all preclinical studies and development work necessary to start Phase I.
“We are grateful to the MJFF for their recognition of our work and their generous support. We see this grant as an expression of confidence in our innovative approach to tackling unmet needs, including apathy, in Parkinson’s disease. With MJFF’s support, we are positioned to advance IRL757 through a crucial Phase I study. It is exciting to have support from the highly reputed MJFF organisation,” said Gunnar Olsson, CEO, IRLAB.
The MJFF is the world’s largest nonprofit funder of Parkinson’s research.